Pharmacy Practice in Focus: Oncology Launches Peer-Review Process

In 2024, Pharmacy Practice in Focus: Oncology welcomes the launch of the peer-review process, with this issue featuring the first peer-reviewed paper. The publication looks to embrace the rigor and increased depth that peer review can bring to each issue.

Image credit: lexiconimages | stock.adobe.com

As such, we are looking for qualified reviewers who may be interested in participating as peer reviewers for the publication. If interested, please reach out to Managing Editor Alana Hippensteele at ahippensteele@mjhlifesciences.com with information regarding your background, qualifications, and research areas of interest for the purposes of participating as a reviewer.

In 2024, we are particularly looking forward to publishing original research from the field of oncology pharmacy with a focus on precision medicine, qualitative and/or quantitative impact of pharmacist-led initiatives, advancements in immunotherapy, biosimilars in oncology, targeted therapies, biomarker development, combination therapies, oral chemotherapy management, palliative care and symptom management, quality improvement and patient safety, management of oncology drug shortages, health care policy and reimbursement, and artificial intelligence and big data. We welcome the opportunity to review and support the dissemination of these valuable research results and findings to the field.

In this issue, on page 14, the peer-reviewed paper “A Review of Anti-HER2 Targeted Agents in Non-Breast Solid Tumors” by Megan Alhadeff, PharmD, MBA; Tiffany Tam, PharmD, BCOP; and Hanh Bui, PharmD, sheds light on the current utilization of anti-HER2 targeted therapy to treat several non-breast solid tumors in the setting of advanced disease. While HER2-targeted therapies have been utilized primarily in breast cancer, the use of anti-HER2 targeted agents is rapidly changing the treatment landscape of other solid cancers.

In the cover story on page 10, authors Yijun Cai, PharmD candidate, and Amir Ali, PharmD, BCOP, discuss the evolving landscape of therapies for patients with chronic lymphocytic leukemia, with a focus on each therapy’s distinct mechanisms, safety profiles, and implications for patients’ quality of life. Additionally, on page 43, authors Valassia Antigone Theocharides, PharmD candidate; Luisa Giannangelo, RPH, MBA; Jessie Modlin, PharmD, BCOP; Tesnim Shash, PharmD candidate; and Sukeina Nasser, PharmD, RPH, CPH, PACS, discuss novel combination therapies in relapsed/refractory classical Hodgkin lymphoma.

In 2024, we look forward to the insights and discussions we will see unfold in the pages of Pharmacy Practice in Focus: Oncology.